scholarly journals Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials

2019 ◽  
Vol 11 (3) ◽  
pp. 640-646
Author(s):  
Naoko Tajima ◽  
Jun‐ichi Eiki ◽  
Taro Okamoto ◽  
Kotoba Okuyama ◽  
Masaru Kawashima ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Type 2 Diabetes Mellitus ◽  
Japanese Patients ◽  
Pooled Analysis ◽  
Glucose Lowering ◽  
Factors Associated

scholarly journals Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

2017 ◽  
Vol 20 (3) ◽  
pp. 620-628 ◽  
Author(s):  
Serge Jabbour ◽  
Jochen Seufert ◽  
Andre Scheen ◽  
Clifford J. Bailey ◽  
Cathrina Karup ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Type 2 Diabetes Mellitus ◽  
Safety Data ◽  
Pooled Analysis

scholarly journals Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials

2019 ◽  
Vol 10 (6) ◽  
pp. 2201-2217 ◽  
Author(s):  
Atsunori Kashiwagi ◽  
Marina V. Shestakova ◽  
Yuichiro Ito ◽  
Masahiro Noguchi ◽  
Wim Wilpshaar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Type 2 Diabetes Mellitus ◽  
Phase Ii ◽  
Pooled Analysis

scholarly journals Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin

2016 ◽  
Vol 19 (1) ◽  
pp. 72-79
Author(s):  
Olga Yuryevna Sukhareva ◽  
Marina Vladimirovna Shestakova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Diabetes Mellitus Type 2 ◽  
Glucose Lowering ◽  
Patients With Diabetes ◽  
Difficult Issue

Intensification of antihyperglycaemic treatment in patients with poorly controlled type 2 diabetes mellitus who were on insulin therapy remains a difficult issue. Results from clinical trials with the sodium-glucose linked transporter (SGLT-2) inhibitor dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus using insulin are summarised and discussed in the article.

Sign in / Sign up

Export Citation Format

Share Document